A novel approach for quantification of the future unmet medical need in right ventricular dysfunction.
Epidemiology
Portfolio management
Right ventricular dysfunction
Unmet medical need
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
21
06
2021
revised:
04
12
2021
accepted:
22
12
2021
pubmed:
28
12
2021
medline:
27
4
2022
entrez:
27
12
2021
Statut:
ppublish
Résumé
Although 'unmet medical need' (UMN) is an increasingly used term in the healthcare sector instrumental to the approximate value of drug discovery projects relevant to portfolio management, no standardized approach exists for its quantification. Especially in diseases with different comorbidities, high patient heterogeneity, and incomplete epidemiological data, it is difficult to judge the need for new therapies. The approach presented here combines an expert assessment of key UMN indicators related to the individual patient with a literature search to collect epidemiological data describing the corresponding patient population with its underlying heterogeneity. This assessment supports decision-making within the portfolio management process in larger research and development organizations.
Identifiants
pubmed: 34958958
pii: S1359-6446(21)00571-7
doi: 10.1016/j.drudis.2021.12.019
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1326-1331Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest At the time of the investigation, the following authors were employees of Bayer AG: L.K.S., J.H., H.T., and T.M.